- Home
- SOPH vs IMAB Comparison
SOPH vs IMAB Comparison
Compare SOPH & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- IMAB
- Stock Information
- Founded
- SOPH 2011
- IMAB 2014
- Country
- SOPH Switzerland
- IMAB United States
- Employees
- SOPH N/A
- IMAB N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- IMAB Health Care
- Exchange
- SOPH Nasdaq
- IMAB Nasdaq
- Market Cap
- SOPH 219.8M
- IMAB 200.9M
- IPO Year
- SOPH 2021
- IMAB 2020
- Fundamental
- Price
- SOPH $3.61
- IMAB $2.11
- Analyst Decision
- SOPH Buy
- IMAB Strong Buy
- Analyst Count
- SOPH 1
- IMAB 3
- Target Price
- SOPH $7.00
- IMAB $6.33
- AVG Volume (30 Days)
- SOPH 43.0K
- IMAB 392.1K
- Earning Date
- SOPH 08-05-2025
- IMAB 05-15-2025
- Dividend Yield
- SOPH N/A
- IMAB N/A
- EPS Growth
- SOPH N/A
- IMAB N/A
- EPS
- SOPH N/A
- IMAB N/A
- Revenue
- SOPH $67,173,000.00
- IMAB N/A
- Revenue This Year
- SOPH $16.13
- IMAB N/A
- Revenue Next Year
- SOPH $23.80
- IMAB N/A
- P/E Ratio
- SOPH N/A
- IMAB N/A
- Revenue Growth
- SOPH 4.66
- IMAB N/A
- 52 Week Low
- SOPH $2.58
- IMAB $0.60
- 52 Week High
- SOPH $4.92
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- SOPH 58.33
- IMAB 49.47
- Support Level
- SOPH $3.36
- IMAB $2.01
- Resistance Level
- SOPH $3.76
- IMAB $2.25
- Average True Range (ATR)
- SOPH 0.20
- IMAB 0.13
- MACD
- SOPH -0.00
- IMAB -0.03
- Stochastic Oscillator
- SOPH 72.31
- IMAB 25.00
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).